Prestige Consumer Healthcare Inc. (NYSE:PBH) Stake Lifted by Vanguard Group Inc.

Vanguard Group Inc. lifted its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 1.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,756,138 shares of the company's stock after purchasing an additional 63,375 shares during the quarter. Vanguard Group Inc. owned about 11.59% of Prestige Consumer Healthcare worth $352,391,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in PBH. GAMMA Investing LLC acquired a new stake in Prestige Consumer Healthcare during the 4th quarter worth about $25,000. Pacer Advisors Inc. lifted its position in Prestige Consumer Healthcare by 85.7% during the 4th quarter. Pacer Advisors Inc. now owns 442 shares of the company's stock worth $27,000 after acquiring an additional 204 shares during the period. Principal Securities Inc. acquired a new stake in Prestige Consumer Healthcare during the 4th quarter worth about $29,000. ORG Partners LLC acquired a new stake in Prestige Consumer Healthcare during the 4th quarter worth about $36,000. Finally, Parallel Advisors LLC lifted its position in Prestige Consumer Healthcare by 42.5% during the 4th quarter. Parallel Advisors LLC now owns 714 shares of the company's stock worth $44,000 after acquiring an additional 213 shares during the period. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Price Performance

Shares of Prestige Consumer Healthcare stock traded down $0.77 on Friday, hitting $68.85. The company's stock had a trading volume of 509,252 shares, compared to its average volume of 252,984. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.02 and a current ratio of 3.20. Prestige Consumer Healthcare Inc. has a 1 year low of $56.34 and a 1 year high of $75.31. The firm has a fifty day moving average price of $67.22 and a 200-day moving average price of $66.67. The company has a market capitalization of $3.44 billion, a price-to-earnings ratio of 16.51, a price-to-earnings-growth ratio of 1.97 and a beta of 0.50.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Tuesday, May 14th. The company reported $1.02 earnings per share for the quarter, missing the consensus estimate of $1.14 by ($0.12). Prestige Consumer Healthcare had a net margin of 18.60% and a return on equity of 13.48%. The business had revenue of $277.00 million during the quarter, compared to analysts' expectations of $287.42 million. During the same quarter in the prior year, the firm earned $1.07 EPS. Prestige Consumer Healthcare's revenue for the quarter was down 3.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.42 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on PBH. Canaccord Genuity Group reiterated a "buy" rating and set a $80.00 price objective on shares of Prestige Consumer Healthcare in a research note on Tuesday, May 21st. StockNews.com lowered Prestige Consumer Healthcare from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 21st. Finally, DA Davidson upgraded Prestige Consumer Healthcare from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $65.00 to $93.00 in a research note on Friday, June 21st. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $98.25.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.